Cell News and Research

RSS

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

PLK1 crucial for proper functioning of cancer cells, researchers reveal

One of the main indicators for determining the activity of a tumour or cancer is cell division. Cancer cells divide more than other types and the genes and molecules involved in the process of division are, often, targets for identifying and treating certain types of cancer.

26 Jun 2013

Scientists examine molecular similarities in human and canine B-cell lymphoma

Humans and their pet dogs are close, so close that they both develop a type of cancer called diffuse large B-cell lymphoma. In humans it's the most common lymphoma subtype while in dogs, it's one of the most common cancers in veterinary oncology.

26 Jun 2013

A paradigm shift for treatment of muscular dystrophy

Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.

26 Jun 2013

Caspase-2 protein contributes to cognitive decline associated with Alzheimer's disease

Researchers at Columbia University Medical Center have demonstrated that a protein called caspase-2 is a key regulator of a signaling pathway that leads to cognitive decline in Alzheimer's disease.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

Researchers from Case Western Reserve University School of Medicine have developed an unprecedented approach to restore nitric oxide to donated blood, a breakthrough that could dramatically reduce harmful effects from transfusions.

26 Jun 2013

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells.

26 Jun 2013

Research paper reveals Cav-1 protein's role in prostate tumor microenvironment

Researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute have uncovered for the first time the vital role a popular protein plays in the stroma, the cell-lined area outside of a prostate tumor.

26 Jun 2013

UW receives $10 million to develop paper-based pathogen identification test

The University of Washington has received nearly $10 million from the U.S. Department of Defense to continue a project aimed at building a small, paper-based device that could test for infectious diseases on-demand in areas where diagnostic capabilities are limited.

26 Jun 2013

Planktonic bacteria streamline their genetic makeup to become lean, mean survival machines

Planktonic bacteria inhabiting the world's oceans have streamlined their genetic makeup to become lean, mean survival machines, according to new research by an international team of researchers, including microbiologists at the University of British Columbia.

25 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Study shows absence of gene leads to early onset of more serious disease in MS animal model

Scientists led by a UCSF neurology researcher are reporting that they have identified the likely genetic mechanism that causes some patients with multiple sclerosis (MS) to quickly progress to a debilitating stage of the disease while other patients progress much more slowly.

25 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Study suggests new ways to maximize delivery of RNA strands

Nanoparticles that deliver short strands of RNA offer a way to treat cancer and other diseases by shutting off malfunctioning genes. Although this approach has shown some promise, scientists are still not sure exactly what happens to the nanoparticles once they get inside their target cells.

25 Jun 2013

Panasonic’s CO2 cell culture incubators deliver outstanding environmental reliability

Increasingly stringent regulation and the need for absolute sample security when working with human materials heightens the need for laboratory instrumentation that performs to the highest standards. Panasonic MCO-19 CO2 cell culture incubators deliver outstanding environmental reliability.

From PHC Europe B.V. 25 Jun 2013

BioLife Solutions, HemaCare enter into strategic partnership

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, and HemaCare Corporation, a leading supplier of blood derived cells and components for research and clinical applications, today announced a strategic relationship wherein HemaCare will market BioLife's HypoThermosol and CryoStor biopreservation media products and HemaCare's blood derived cells to the research and clinical communities.

25 Jun 2013

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

UCSF scientists explore how Dact1 mutations contribute to psychiatric disorders

Gene mutations that cause cell signaling networks to go awry during embryonic development and lead to major birth defects may also cause subtle disruptions in the brain that contribute to psychiatric disorders such as schizophrenia, autism, and bipolar disorder, according to new research by UC San Francisco scientists.

25 Jun 2013

Cell News and Research

Eisai submits BELVIQ NDS with Health Canada

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

PLK1 crucial for proper functioning of cancer cells, researchers reveal

Scientists examine molecular similarities in human and canine B-cell lymphoma

A paradigm shift for treatment of muscular dystrophy

Caspase-2 protein contributes to cognitive decline associated with Alzheimer's disease

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Research paper reveals Cav-1 protein's role in prostate tumor microenvironment

UW receives $10 million to develop paper-based pathogen identification test

Planktonic bacteria streamline their genetic makeup to become lean, mean survival machines

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Study shows absence of gene leads to early onset of more serious disease in MS animal model

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Study suggests new ways to maximize delivery of RNA strands

Panasonic’s CO2 cell culture incubators deliver outstanding environmental reliability

BioLife Solutions, HemaCare enter into strategic partnership

Study finds that triple therapy corrects two core defects in type 2 diabetes

UCSF scientists explore how Dact1 mutations contribute to psychiatric disorders

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News